CTMX Q2 2022 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M-21.1% YoY

Gross Profit

$13M100.0% margin

Operating Income

-$30M-233.8% margin

Net Income

-$29M-229.5% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+42.2%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$35M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$260M

Total Liabilities

$211M

Stockholders' Equity

$49M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$16M	-21.1%
Gross Profit	$13M	$16M	-21.1%
Operating Income	-$30M	-$19M	-56.5%
Net Income	-$29M	-$19M	-53.3%